N/A N=80 Video-assisted Anal Fistula Treatment Versus Seton in the Management of High Peri Anal Fistula
Post Operative Pain · Recurrence
Primary: Number of Participants With Recurrence of Disease or Fistula — 5; 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=52 Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy
Pancreas Cancer · Pancreas Disease · Pancreas Adenocarcinoma
Primary: Number of Participants With a Clinically Significant Post-operative Pancreatic Fistula (POPF) — 13 Participants
N/A N=100 A Prospective, Multi-center, Observational Study of the Use of Permacol™ Collagen Paste to Treat Anorectal Fistulas
Anorectal Fistulas
Primary: Fistula Healing in Patients at 6 Months Following Surgery — 56.7; 43.3 percentage of participants
N/A N=86 A Randomized Clinical Trial Comparing Surgisis AFP to Advancement Flap for the Repair of Anal Fistulas
Anal Fistula
Primary: Healing Success — 22; 25 participants — p=0.59
N/A N=2 Pilot Study Evaluating the Safety and Efficacy of a Patient-Specific Enteroatmospheric Fistula Isolation and Management Device Independent of Negative Pressure Wound Therapy
Fistula · Abdominal Injury · Negative Pressure Wound Therapy
Primary: Change in Inpatient Participant Pain Rating
Phase 3 N=168 Closed Suction Drainage and Natural Drainage of the Pancreatic Duct in Pancreaticojejunostomy
Pancreatic Fistula
Primary: Number of Patients With Pancreatic Fistula — 9; 8 participants
Phase 3 N=439 Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Pancreatic Cancer
Primary: To Compare 60-day ≥Grade 3 Pancreatic Complication Rates (Fistula, Leak, and Abscess) as Defined by the MSKCC Surgical Secondary Events System Between Patients Who…
N/A N=298 Prevena™ Incisional Negative Pressure Wound Therapy in Re-operative Colorectal Surgery
Surgical Site Infection
Primary: Occurrence of Superficial Surgical Site Infection — 11; 21; 107; 128 Participants
N/A N=12 Fistula Reintegration Pilot
Female Genital Fistula · Urinary Incontinence
Primary: Percentage of Planned Intervention Sessions That Were Delivered — 96.2 percentage of planned sessions
Phase 2 N=114 A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Pancreatic Leak · Pancreatic Fistula · Pancreaticoduodenal; Fistula
Primary: Combined Clinically Significant Postoperative Pancreatic Fistula and Intra-abdominal Abscess — 8 Participants
N/A N=7 Fluorescent Evaluation of Colorectal Anastamoses
Rectal Neoplasms · Colon Neoplasms · Diverticulitis
Primary: Evaluate the Vascular Supply of the Bowel Intra-operatively and Correlate This With Postoperative Complications Identified During Their Hospital Stay at One Week and One…
N/A N=112 Stoma Closure and Reinforcement Trial
Colon Cancer · Rectal Cancer · Ileostomy - Stoma
Primary: Number of Participants With Wound Occurrences — 0 Participants
N/A N=399 Pancreas Resection With and Without Drains
Pancreas Tumor · Pancreatitis
Primary: 60-day ≥ Grade II Complication Rate — 72; 76 Participants — p=0.804
N/A N=124 Comparison Between Wound Vacuum Dressing and Standard Closure to Reduce Rates of Surgical Site Infections
Surgical Site Infection · Pancreatic Neoplasms · Pancreatic Cancer
Primary: Rate of Surgical Site Infection — 6; 19 Participants — p=0.003
Phase 4 N=120 Parastomal Reinforcement With Strattice
Parastomal Hernia
Primary: Occurrence of Parastomal Hernia in Subjects Undergoing Permanent Abdominal Wall Ostomy Creation With and Without Strattice Fascial Inlay. — 6; 7 participants
Phase 3 N=150 Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula
Crohn's Disease · Complex Perianal Fistula
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 40; 43 Participants
Phase 4 N=74 Post-Operative Drainage Following Lymph Node Dissection
Malignant Melanoma · Carcinoma, Squamous Cell
Primary: Post-operative Wound Drainage. — 892.5; 762.5; 565; 590 ml — p=0.704
N/A N=7 Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus
Peptic Ulcer
Primary: Number of Participants Completing Natural Orifice Translumenal Endoscopic Surgical (NOTES) Repair — 2; 1 participants
Phase 3 N=170 Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection
Injury of Body of Pancreas
Primary: Number of Participants With Biochemical Leak/Grade B Fistula/Grade C Fistula — 25; 16; 3; 5 Participants
N/A N=18 Vacuum Assisted Therapy in Emergent Contaminated Abdominal Surgeries
Gastrointestinal Injury · Complicated Diverticulitis
Primary: Rate of Surgical Site Infection — 5 Participants
N/A N=60 Perianastomotic Drain After Gastrectomy (DRAG)
Gastric Cancer
Primary: a) Number of Participants With High Pain Levels (Using the Visual Analog Scale) — 31; 3 Participants
N/A N=84 Effect of Preoperative Fiber on Postoperative Bowel Function
Constipation · Prolapse, Vaginal
Primary: Time to First Bowel Movement After Surgery — 66.5; 68.3 hours
N/A N=54 Postoperative Virtual Clinical Encounters
Pelvic Organ Prolapse
Primary: Patient Satisfaction Via the Patient Satisfaction Questionnaire -18 — 80.7; 81.2 score on a scale
N/A N=20 Single-Use Negative Pressure Wound Therapy for Free Flap Donor Sites
Surgical Wound
Primary: Progression of Wound Healing — 69.9; 75.6 percentage of skin graft take
Phase 4 N=62 NITI CAR27 (ColonRing) Compression Anastomosis in Colorectal Surgery
Colonic Neoplasms · Rectal Neoplasms · Diverticulitis
Primary: Anastomotic Leakage — 0 participants
N/A N=84 Treatment for Acute Postoperative Voiding Dysfunction
Urinary Retention
Primary: Persistent Retention — 29; 21 participants
N/A N=402 Evaluation of Surgisis Gold Graft for Incision Reinforcement After Open Bariatric Surgery
Hernia · Obesity
Primary: Incisional Hernia — 32; 38 participants — p=0.60
Phase 4 N=94 Oral Nutrition After Regular Radical Cystectomy
Post Cystostomy
Primary: the Postoperative Length of Stay — 18; 14 day — p=<0.001
N/A N=150 Intraoperative Pathway in DIEP Flap Breast Reconstruction
Breast Cancer
Primary: Operative Time — 8.2; 6.9 hours
Phase 2 N=33 Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease
Crohn's Disease
Primary: Safety and Tolerability of Ciprofloxacin — 25; 11; 9; 1 Adverse events